• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

At the BSIO Award Symposium, the winners of our Female Independence and Mini-Lab Awards will share their outstanding work in exciting presentations.

The BSIO Female Independence Award aims to support young women in science working in the field of cancer research, who have recently established their own laboratory or are transitioning from a postdoc to a group leader. 

The BSIO Mini-Lab Award aims to support young scientists working in the field of cancer research, who demonstrate high productivity and independence with an ambitious academic prospect.

We hereby cordially invite you to the symposium presentations and look forward to inspiring discussions. 

The event will take place in person. 
The "3-G" rules apply and a medical mask  is mandatory insight the Audimax during the symposium. 
Please allow 20 to 30 minutes for waiting at the entrance to the clinic premises. As a Charité external (without a Charité service card), you must prove that you meet one of the "3Gs" (tested, vaccinated or recovered) when entering the premises

For presentation at the campus entrance, please find below a downloadable invitation in German and English (pdf) to the symposium.

When? September 29, 2021
Where? Audimax at Forum 3, Charité - Universitätmedizin Berlin, Campus Virchow-Klinikum (CVK), Berlin, Germany.
Registration: Registration in advance by email to bsio@ charite.de is desirable, as room capacity is limited.
Registration fee: 0 €


16:00 - 16:30 Registration
16:30 - 16:40 Welcome
Female Independence Awardees  
16:40 - 17:10 Dr. Stefanie Grosswendt - "Cellular states in development and cancer”
(Chair: Kimberly Hartl)  
17:10 - 17:40 Dr. Soulafa Mamlouk - “Patient specific evaluation of tumor evolution in colorectal cancer”
(Chair: Ajay Mohan)  
Mini-Lab Awardee  
17:40 - 18:00 Inmaculada Martínez Reyes, PhD - “Metabolic networks in tumor immunity”
(Chair: Laura Grunewald)  

BSIO Awardees

Dr. Stefanie Grosswendt

Dr. Stefanie Grosswendt investigates how the transcriptional configurations of “cell states”, determine cell function in development and cancer at Berlin Institute of Health, Charité, BIMSB/Max Delbrück Center.

She develops strategies to analyze cells within their tissue context and identify the communication events responsible for specific cellular decisions and behaviors.


Dr. Soulafa Mamlouk

Dr. Soulafa Mamlouk investigates the evolution of resistance to cancer therapy in colorectal cancer at the Institute of Pathology of the Charité.

She uses evolutionary concepts to study cancer progression and resistance under selective pressure, such as during cancer therapy.




Inmaculada Martínez Reyes, PhD

Inmaculada Martínez Reyes investigates in the Laboratory of Prof. Thomas Blankenstein at the Max Delbrück Center for Molecular Medicine metabolic pathways involved in driving immune suppression or exhaustion within the tumor microenvironment.


Invitation to the Symposium (available in DE and EN)

Explanation of the "3G" specifications

Visitors must provide a certificate confirming their negative rapid antigen or PCR test. Certificates must be issued by a test center/unit or pharmacy. The test result must be no older than 24 hours.

The following shall be exempt from testing provided they can produce the relevant documentation:

Fully vaccinated individuals

Individuals shall be considered fully vaccinated if they have received both scheduled doses of the relevant vaccine and the second dose was administered at least 14 days before the date of the planned visit. Fully vaccinated individuals must produce a vaccination passport/certificate to confirm their status.

Individuals who have recovered from COVID-19 and received one vaccine dose

Individuals shall be considered to have recovered from COVID-19 if they can produce proof of prior illness. Recovered individuals will need to provide proof of a positive PCR result along with proof of vaccination (at least one dose) six months after recovery. This vaccine dose must have been administered at least 14 days before the date of the planned visit. 

Persons with respiratory infections are prohibited from entering.